To enhance the antitumor effect of IDHmut inhibitors, particularly in low-grade gliomas, a few preclinical studies investigated synthetic lethal interactions of these inhibitors, with other reagents such as NAMPT inhibitors [48], Bcl-2 inhibitors [49], NRF2 inhibitors [50], PARP inhibitors [51], and tyrosine kinase inhibitors [52]. Here, BCL2 is linked to central nervous system cancer.